medigraphic.com
ISSN 1561-302X (Print)

2019, Number 4

<< Back Next >>

Rev cubana med 2019; 58 (4)

Clinical and functional comparison between patients diagnosed with severe and very severe chronic obstructive pulmonary disease

Robainas PI

Language: Spanish
References: 53
Page: 1-21
PDF size: 326.92 Kb.


ABSTRACT

Introduction: Chronic obstructive pulmonary disease is a respiratory problem with the highest prevalence and socioeconomic impact in the world, despite being a potentially preventable disease.
Objective: To compare clinically and functionally patients diagnosed with severe and very severe chronic obstructive pulmonary disease.
Methods: A descriptive study was carried out in patients with a clinical-spirometric diagnosis of severe or very severe chronic obstructive pulmonary disease, according to sex. They were assisted at the Benéfico Jurídico Neurologic Hospital from September 2015 to March 2017. It was used for the quantitative variables the mean and standard deviation and the statistical significance analysis using the student's t test. Fifty patients formed the sample, 25 men and 25 women.
Results: Women had fewer exacerbations with a means difference of 0.7 (95% CI male 2.4- 3.1; female 1.6-2.5; p = 0.01). The dyspnea sensation was greater in men, with a means difference of 0.6 (95% CI male 2.4-3.1; female 1.8-2.5; p = 0.00). In the exercise capacity according to PM6M, women achieved better percentages than predicted with a means difference of 12.8% from (95% CI male 49.2-63.5; female 62.6-75.7; p = 0.00).
Conclusions: Men present more complications than women with the same spirometrical characteristics.


REFERENCES

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016[acceso: 10/11/2014]:6-10. Disponible en: http://www.goldcopd.org

  2. Organización Panamericana de la Salud. Sistema de información regional de mortalidad 2014[acceso: 10/11/2014]. Disponible en: http://www.paho.org/ncds

  3. Chronic obstructive pulmonary disease (COPD). Facts heet Nº315. Geneva: World Health Organization; 2013[acceso: 12/03/2016]. Disponible en: http://bit.ly/1nytnII

  4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014[acceso: 10/11/2016]. Disponible en: http://bit.ly/1qucRLp

  5. Organización Panamericana de la Salud. Informe sobre Control del Tabaco para la Región de las Américas. Washington D.C. OPS; 2013[acceso: 10/11/2014]. Disponible en: http://bit. Ly/1r1SO1B

  6. Jiménez Ruiz CA, De Granda Orive JI, Solano Reina S, Riesco Miranda JA, De Higes Martinez E, Pascual Lledó JF, et al. Normativa sobre tratamiento del tabaquismo en pacientes hospitalizados. Arch Bronconeumol. 2016. http://dx.doi. org/10.1016/j.arbres.2016.11.004

  7. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC). Arch Bronconeumol. 2017;53(6):324-35.

  8. Almagro P, Sangil A, Custardoy J, San Román Terán C, Martín Escudero JC, Díez Manglano J, et al. Enfermedad pulmonar obstructiva crónica. ¿Los tiempos están cambiando? Rev Clin Esp. 2013;213:152-7.

  9. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309:2353-61.

  10. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD Ex- ecutive Summary. Arch Bronconeumol. 2017;53:128-49.

  11. Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, et al. Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J. 2018;51:1702146.

  12. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, et al. For the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characteristics, stability and outcomes of the GOLD 2011 copd groups in the ECLIPSE cohort. Eur Respir J. 2013;42:636-42.

  13. Di Marco F, Verga M, Reggente M, Maria CF, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100:1767-74.

  14. Legrá N, Grave de Peralta YT, Riverón I, del Campo E, Silvera S. Caracterización clínico epidemiológica de pacientes con enfermedad pulmonar obstructiva crónica. MEDISAN. 2014;18:1274.

  15. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med. 2013;187:347-65.

  16. Oficina Nacional de Estadísticas e Información. Anuario Estadístico de Cuba. 2018. La Habana 2018. ISNN 0574-6132.

  17. Ancochea J, Miravitlles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: cuantificación del problema, determinantes y propuestas de acción. Arch Bronconeumol. 2013;49:223-9.

  18. Calle M, Alcázar B, Soriano JB, Soler-Cataluña JJ, Rodríguez JM, Fuentes M, et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulm Dis. 2017:12:417-26.

  19. Aryal S, Enrique Díaz Guzmán E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162:208-18.

  20. Gutiérrez SA, Domínguez A, Valenzuela A. Eficacia de los criterios clínicos y factores de riesgo en el diagnóstico de enfermedad pulmonar obstructiva crónica. Med Int Mex. 2014;30:247-56.

  21. Hardin M, Foreman M, Dransfield MT, Hansel N, Han MK, Cho MH, et al. Sex-specific features of emphysema among current and former smokers with COPD. Eur Respir J. 2016;47:104-12.

  22. Aryal S, Díaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J COPD. 2014;9:1145-54.

  23. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10: 24.

  24. Conté JE, Murria RP, Buist AS, Robert A, Wise RA, Lindgren PG, et al. Changes in smoking status affect women more than men: results of the lung health study. American Journal of Epidemiology. 2003. https://doi.org/10.1093/aje/kwg083

  25. Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, et al. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis. 2013;8:259-71.

  26. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107:10-22.

  27. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructi- ve Lung Disease Report: GOLD Executive Summary. Arch Bronconeumol. 2017;53:128-49.

  28. López Campos JL, Asensio Cruz MI, Castro Acosta A. Results from an Audit Feedback Strategy for Chronic Obstructive Pulmonary Disease In Hospital Care: A Joint Analysis from the AuDIPOC and European COPD Audit Studies: Plos One 2014; 9: e110394.

  29. de Torres CG, Cote MV, Lopez C, Casanova O, Díaz JM, Marine V. et al. A. Aguirre- Jaime and B.R. Celli: Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33(3):528-35.

  30. Enríquez Rodríguez AI. Diferencias entre hombres y mujeres con enfermedad pulmonar obstructiva crónica atendidos en las consultas externas de neumología. Arch Bronconeumol. 2014;57:26-4.

  31. Almagro P, López García F, Cabrera FJ, Montero L. Comorbidity and gender-related differences in pathients hospitalized for COPD.The ECCO study. P. Respiratory Medicine. 2010;104:253-59.

  32. Arenas de Larriva L, Caballero Ballesteros N, Pascual Martínez L, Sánchez Osuna, LM. Resultados en calidad asistencial de la hospitalización de la exacerbación grave de la epoc en un hospital de tercer nivel y comparativa con dos hospitales comarcales.articulo original.Rev Esp Patol Torac. 2016;28(4)192-7.

  33. Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, et al. COPD Biomarker Qualification Consortium. The 6-Minute-Walk Distance Test as a Chronic Obstruc- tive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;194:1483-93.

  34. Gutierrez Veloz O. Caracterización epidemiológica, clínica y espirométrica de pacientes con EPOC en el Policlínico Docente Centro de Santi Spíritus. 2007. Disponible en: http://www.monografias.com

  35. Venero Fernández SJ. Epidemiología y estrategia para manejo de las enfermedades respiratorias crónicas en Cuba. Taller de intercambios de experiencias en materias de cuidados integrales al paciente con enfermedad pulmonar obstructiva crónica. La Habana del 23 al 27 de noviembre de 2015.

  36. Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S, et al. Effects of Allergic Phenotype on Respiratory Symptoms and Exacerbations in Patients with COPD. Am J Respir Crit Care Med. 2013;188:187-92.

  37. Gruenberger JB, Vietri J, Keininger DL, Mahler DA. Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:937-44.

  38. Martín Palmero Á, Castro Alija MJ, Gómez Candela C. Evaluación y tratamiento nutricional en el paciente con EPOC. Monogr Arch Bronconeumol. 2017;3:218-27.

  39. Zulueta JJ, Wisnivesky JP, Henschke CI, Yip R, Farooqi AO, McCauley DI, et al. Emphysema scores predict death from COPD and lung cancer. Chest Medline. 2012;141:1216-23.

  40. de Vries K, Booiji H, Goei JT. Hyperreactivity of the bronchial tree to drugs, chemicals and physical agents. In: Orie NJM, Sluiter HJ, eds. Bronchitis II. Assen, the Netherlands: Royal Van Gorcum, 1964.

  41. Johannessen A, Omenaas E, Bakke P, Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. int j tuberc lung dis. 2005;9(8):926-32.

  42. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest. 2004;125:892-900.

  43. de Torres JP, Casanova C, Montejo de Garcini A, Aguirre Jaime A, R Celli B. COPD heterogeneity: Gender differences in the multidimensional BODE index. International Journal of COPD. 2007:2(2):151-55.

  44. Miravitlles M, de la Roza C, Morera J, Montemayor T, Gobartt E, Martin A, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respiratory Medicine. 2006;100:1973-80.

  45. Montes de Oca, Tálamo C, Halbert RJ, Perez Padilla, R López MV, Muiño A et al. Health status perception and airflow obstruction in five American Cities. The PLATINO study. Respir Med. 2008;102:624-50.

  46. Barreiro E, Ferrer D, Sánchez F, Minguella J, Marín Corral J, Martínez Llorens J, et al. Inflammatory cells and apoptosis in respiratory and limb muscles of patients with COPD. J Appl Physiol. 2011;111(3):808-17.

  47. Espinosa MJ, Peña C, Soto EJ, Jareño J, Miravitlles M. Variabilidad de los síntomas respiratorios en la EPOC grave. Arch Bronconeumol. 2012;48:37.

  48. Van den Bemt L, Smeele IJM, Kolkman M, Grol R, van Weel C. Low body mass index, airflow obstruction, and dyspnea in a primary care COPD patient population. Primary Care Respiratory Journal. 2010;19:118-23.

  49. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High resolution computed tomography scanning in alpha 1 antitrypsin deficiency, relationship to lung function and health status. Eur Resp J. 2001;17:1097-104.

  50. De Torres JP, Casanova C, Hernandez C, Abreu J, Aguirre-Jaime A, Celli BR. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128:2012-6.

  51. De Torres JP, Casanova C, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respir Res. 2007;8:169;18.

  52. Mayoralas Alises S, Díaz Lobato S, Antón E, Ribera X, Unzueta I, Martin A. Características clínicas y sociodemográficas de mujeres diagnosticadas de enfermedad pulmonar obstructiva crónica (EPOC) en España: estudio ECME. Rev Patol Respir. 2016;19:3-10.

  53. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44-52.




2020     |     www.medigraphic.com